Introduction
With the development of modern medical and health care, the large-scale use or abuse of broad-spectrum antibiotics, glucocorticoids, and immunosuppressants, the rise of organ transplantation technology, and the increasingly diverse means of tumour radiotherapy and chemotherapy have brought benefits to human beings but have also brought new crises [1]. According to a survey of the prevalence of fungal diseases in multiple countries, more than 3 million people a year now contract pulmonary mycosis, a 41-fold increase in 32 years [2]. In 2022, the World Health Organization (WHO) released the list of health-threatening fungi for the first time, and many opportunistic pathogenic fungi entered human view. Aspergillus fumigatus, Candida auris, Cryptococcus neoformans and Candida albicans were listed as the Critical Priority Group in the fungal list, among which Aspergillus fumigatus and Candida auris mainly cause respiratory infections [3].
As fungi that are extensively tested in clinical settings, both Aspergillus and Cryptococcus can cause primary infections of a single organ (usually the lung) or disseminated infections resulting in multiorgan dysfunction, such as cryptococcal meningitis and invasive pulmonary aspergillosis [4]. Even in immunocompetent patients, these infections have a high mortality rate [5]. Therefore, accurate diagnosis and timely antifungal therapy are particularly important to avoid a misdiagnosis or a missed diagnosis, which may result in death or progression to severe chronic disease.
Anzeige
Reports of single opportunistic pathogenic fungal infections causing pneumonia are common, while studies on coinfection of fungi are lacking. Although the incidence of coinfection of fungal disease is not high, its clinical presentation is nonspecific and lacks sufficiently sensitive noninvasive diagnostic methods, which may lead to underestimation of its incidence and make it prone to a misdiagnosis and a missed diagnosis. Reports of coinfection of Aspergillus and Cryptococcus are rare, and their characteristics have not been described in detail. This study aims to provide clinical experience for the early diagnosis and standardized treatment of this disease by reporting a series of cases while reviewing previous reports on coinfection of Aspergillus and Cryptococcus.
Method
Retrospective study
A retrospective study was conducted on patients diagnosed with pulmonary cryptococcosis and pulmonary aspergillosis who were HIV-negative. The time range was from January 1st, 2014, to December 31st, 2022. All patients provided informed consent and received support from the First Affiliated Hospital of Guangzhou Medical University.
Systematic review
Search strategy
We searched PubMed, Web of Science, Embase, and BIOSIS Library for 68 original case reports and cohort studies on pulmonary cryptococcosis with pulmonary aspergillosis published in English between January 1, 1985, and December 31, 2022. We used the keywords “Aspergillus and cryptococcus and coinfection,” “Coinfection with cryptococcus and aspergillus,” “((cryptococcus) AND (aspergillus)) AND (coinfection),” and “Pulmonary cryptococcosis with pulmonary aspergillosis.” The references of the retrieved articles were reviewed for additional relevant citations. The abstracts of all identified articles were viewed, and the full-text versions of relevant articles were retrieved for data extraction and analysis [6‐11]. (Fig. 1)
Fig. 1
Flow chart of the literature included in the review and the selected cases
×
![]()
Pulmonary cryptococcosis complicated with pulmonary aspergillosis definition
Histopathological examination of pathogenic bacterial infection is the diagnostic criterion [12]. Positive results can be obtained from histopathological, cytological, or direct microscopic examination of normally sterile abnormal sites that are clinically or radiographically consistent with an infectious disease process, using aseptic techniques to obtain specimens (excluding bronchoalveolar lavage fluid, BALF), or from culture-positive/fungal DNA amplified by PCR and DNA sequencing in formalin-fixed, paraffin-embedded tissues where fungi are found. Invasive pulmonary fungal disease requires at least one host factor, one clinical feature, and one mycological evidence and is only applicable to immunodeficient patients. The diagnosis comes from the 2019 EORCT/MSGERC Guidelines for Invasive Mycosis. Mycological evidence is an important basis for clinical diagnostic criteria for pulmonary aspergillosis and pulmonary cryptococcosis, which can be in the sputum, BALF, etc., or from the culture of any mould and the microscopic detection of any suggestive mould components. For Aspergillus disease, GM test plasma, serum, BAL detected antigen or titre ≥ 1.0, plasma titre ≥ 0.7, or BALF titre ≥ 0.8 can be used. Continuous positive PCR test results can also lead to a clinical diagnosis.
Inclusion and exclusion criteria
Inclusion Criteria: (1) HIV-negative patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis as defined above were included for analysis. (2) Original studies reporting patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis as defined above were included for analysis. (3) Informed consent was obtained from the patients.
Anzeige
The exclusion criteria were as follows: (1) articles on mycology, diagnostics, antifungal susceptibility and experimental animal studies; (2) general review articles on pulmonary cryptococcosis and pulmonary aspergillosis; and (3) case reports or series involving HIV-positive individuals. For duplicate publications, the most recent article was used for data extraction.
Result
Demographic and clinical characteristics of patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis
In this retrospective study and literature review, we investigated 11 patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis. The study focused on HIV-negative patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis. The patients in this retrospective study were from the First Affiliated Hospital of Guangzhou Medical University, and a total of 5 patients were included. Four patients underwent histological examination of bronchoscopy biopsy or percutaneous lung puncture, and the remaining patients underwent histological examination after pulmonary lobectomy. There were 6 cases from 6 case reports after excluding systematic reviews and duplicate reports. Among the 11 patients, 7 were from China, 1 was from Taiwan, 2 were from the United States, and 2 were from Japan. There were 3 female and 8 male patients, with 7 patients in the younger age group (18–44 years), 2 patients in the middle-aged group (45–59 years), and 2 patients in the elderly group (60–74 years), with a median age of 38 (31–74 years).
Cough (6/11), fever (3/11), sputum (2/11), haemoptysis (2/11), and chest pain (2/11) were the most common clinical symptoms. One patient had gastrointestinal symptoms of anorexia, and another patient had weight loss. Notably, 3 patients did not have any clinical symptoms and were found to have pulmonary shadows or cavities during physical examination, prompting them to seek medical attention. Four patients were diagnosed with both pulmonary cryptococcosis and pulmonary aspergillosis through histological evidence. Six patients were initially diagnosed with pulmonary cryptococcosis and later diagnosed with pulmonary aspergillosis after treatment, and 1 patient was diagnosed clinically. The remaining 10 patients were diagnosed with invasive methods, including transbronchial lung biopsy, CT-guided lung puncture biopsy, VATS lung biopsy, and surgical lung resection, with pulmonary tissue pathology confirming the diagnosis [6‐11] (Table 1).
Table 1
Basic patient information
NO. | Country | Age | Gender | cardinal symptom | Underlying diseases/Drug use | Therapeutic process | Ultimate treatment | Prognosis | Means of diagnosis |
|---|---|---|---|---|---|---|---|---|---|
P1 | China | 50 | Female | Cough, Bloodshot sputum | Diabetes | Pulmonary cryptococcosis → Fluconazole 6 month (poor response) → right lower lobe resection. Pathology: Cryptococcus + Aspergillus | Voriconazole | Cure | Thoracoscopic lobectomy |
P2 | China | 38 | Male | Physical examination revealed lung shadow | / | Pulmonary cryptococcosis → Voriconazole 5 m (no absorption) to Fluconazole 3 m (no absorption) → Pathology slide consultation: Cryptococcus + Aspergillus | Voriconazole | Cure | TBLB |
P3 | China | 35 | Male | Cough, Phlegm, Fever | Horseshoe kidney | Pulmonary cryptococcosis → Fluconazole 10 m (first reduced and then increased) →pathology: Aspergillus | Voriconazole | Cure | TBLB + CT-guided percutaneous lung biopsy |
P4 | China | 53 | Male | Physical examination revealed a cavity in the right lung | Diabetes | Pulmonary cryptococcosis → Fluconazole 2 m (first reduced lesion, then no change) → Pathology: pulmonary Aspergillus with cryptococcus | Voriconazole | Cure | TBLB |
P5 | China | 32 | Male | Physical examination revealed a shadow of the lower left lung | / | Pulmonary cryptococcosis → Fluconazole (lesion enlargement)→ Pathology: pulmonary Aspergillus with cryptococcus | Voriconazole | Improvement | TBLB |
P6 | America16 | 31 | Male | Chest pain, Dry cough, Night sweats | / | Pulmonary cryptococcosis + Aspergillus disease → amphotericin B (cavity enlargement) → lobectomy → amphotericin B | Amphotericin B + lobectomy | Improvement | Lobectomy |
P7 | China15 | 33 | Female | Chest pain, Fever | Systemic lupus erythematosus (glucocorticoid hormone + azathioprine) | Pulmonary aspergillosis + pulmonary cryptococcosis → amphotericin B + Fluconazole | Amphotericin B + Fluconazole | Improvement | VATS lung biopsy |
P8 | Japan14 | 74 | Male | Dry cough | Tuberculosis | Suspected malignancy of the left inferior void → lobectomy → pathology: pulmonary aspergillosis + pulmonary cryptococcosis | Not mentioned | Not mentioned | Thoracoscopic lobectomy |
P9 | Japan13 | 64 | Male | Two cavities in the lungs with aspergillus pellets | Rheumatoid arthritis (glucocorticoid + cyclophosphamide) | TBLB was used to diagnose Cryptococcus pneumoniae with fungal spherules → Fluconazole →VATS, and PCR confirmed cryptococcus with aspergillus infection | Fluconazole | Not mentioned | VATS lung biopsy |
P10 | China12 | 33 | Male | Haemoptysis | / | Empiric anti-infective + anti-tuberculosis therapy 1 week (no improvement in symptoms) →VATS left lower lobectomy → Pathology: pulmonary Aspergillus + Cryptococcus pulmonary | Amphotericin B + Fluconazole | Cure | Thoracoscopic lobectomy |
P11 | America11 | 69 | Female | Dyspnoea, Fever, Dry cough, Loss of appetite, Fatigue | Post-bone marrow transplantation | Pulmonary cryptococcosis → Flucytosine + amphotericin B liposomes (aggravation of symptoms and CT findings) | Voriconazole | Improvement | Cryptococcal antigen titre 1:640; BALF-GM test was 3.258 |
Laboratory and radiographic characteristics of patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis
Routine blood examination showed that 6/7 patients had a normal white blood cell count, 5/5 had a normal neutrophil count, and 5/5 had a normal lymphocyte count. A total of 5/8 patients had positive serum cryptococcal antigen titres, while 2/8 had positive Aspergillus antigen titres. Seven patients tested negative for the G test, 3 patients did not have G test results mentioned, and 1 patient was not tested for fungal infection at the time and did not have a G test performed. 50% (2/4) of the patients had positive cryptococcal antigen titres in bronchoalveolar lavage fluid, while 2/5 had positive Aspergillus antigen titres. Microbial cultures were positive in 3/11 of the patients, with specimens including sputum, bronchoalveolar lavage fluid, and sputum smears. Partial pathogenic bacteria were detected in 2 patients (2/11) using metagenomic next-generation sequencing (mNGS) technology, with Aspergillus detected in one patient and cryptococcus detected in another (Table 2; Fig. 2A).
Table 2
Laboratory examination and microbiological testing
No. | WBC | NEU | LYM | Cryptococcus antigen test (serum) | Cryptococcus antibody | Aspergillus antigen | aspergillus antibody | G test | Cryptococcus antigen test (BALF) | GM test (BALF) | Pathogen culture | mNGS | Histopathological examination | Initial diagnosis and basis | Final diagnosis and basis | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P1 | 7 | 3.8 | 2.5 | negative | / | negative | / | negative | undetected | undetected | Sputum + BALF culture: Cryptococcus neoformans | / | Lung tissue changed to cryptococcus + Aspergillus infection | Pulmonary cryptococcosis Sputum + BALF culture: Cryptococcus neoformans | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Lung tissue changed to cryptococcus + Aspergillus infection | ||
P2 | 7 | 3.0 | 3.2 | negative | / | negative | / | negative | < 3.2(negative) | 0.267(negative) | negative | / | Lung tissue showed pulmonary cryptococcosis with aspergillus infection | Pulmonary cryptococcosis Lung tissue showed pulmonary cryptococcosis | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Lung tissue showed pulmonary cryptococcosis with aspergillus infection | ||
P3 | 6.98 | 3.6 | 2.6 | > 100.0 ug/L | / | negative | / | negative | 8.701 µg/L | negative | BALF culture: Cryptococcus neoformans | Lung Tissue: Aspergillus fumigatus | Lung tissue showed chronic bronchitis with aspergillus infection | Pulmonary cryptococcosis BALF culture: Cryptococcus neoformans and Cryptococcus antigen test (BALF): 8.701 µg/L | Pulmonary aspergillosis Lung Tissue: Aspergillus fumigatus and Lung tissue mNGS showed aspergillus infection | ||
P4 | 9.9 | 5.8 | 2.8 | negative | / | negative | / | negative | 9.329 µg/L | 0.309 µg/L(negative) | negative | / | Lung tissue showed lesions consistent with pulmonary aspergillus with cryptococcus infection | Pulmonary cryptococcosis Cryptococcus antigen test (BALF): 9.329 µg/L | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Lung tissue showed lesions consistent with pulmonary aspergillus with cryptococcus infection | ||
P5 | 5.7 | 3.4 | 1.6 | positive | / | 2.44 µg/L | / | negative | negative | 2.0479 | negative | BALF: Cryptococcus neoformans | Lung tissue showed pulmonary Aspergillus with cryptococcus infection | Pulmonary cryptococcosis Cryptococcus antigen test(serum): positive, BALF culture: Cryptococcus neoformans | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Lung tissue showed pulmonary cryptococcosis with aspergillus infection | ||
P6 | unreported | unreported | unreported | 1:2 | positive | unreported | / | unreported | unreported | unreported | Sputum smear: Cryptococcus; Sputum culture: Aspergillus fumigatus + Candida albicans | / | Lung tissue changed to cryptococcus + Aspergillus infection | Pulmonary cryptococcosis complicated with pulmonary Lung tissue changed to cryptococcus + Aspergillus infection | Co-infection diagnosis was made at once | ||
P7 | unreported | unreported | unreported | unreported | / | unreported | / | unreported | unreported | unreported | Lung tissue culture: Aspergillus flavus | / | Wrapped Cryptococcus yeast cells and entwined aspergillus filaments were seen in lung tissue | Pulmonary cryptococcosis complicated with pulmonary Wrapped Cryptococcus yeast cells and entwined aspergillus filaments were seen in lung tissue | Co-infection diagnosis was made at once | ||
P8 | unreported | unreported | unreported | undetected | / | undetected | / | undetected | undetected | undetected | Lung tissue culture: Aspergillus and Cryptococcus neoformans | / | The lung tissue showed positive anti-aspergillus antibody for cryptococcus and isolated hypha | Suspected malignancy of the left inferior void | Pulmonary cryptococcosis complicated with pulmonary aspergillosis The lung tissue showed positive anti-aspergillus antibody for cryptococcus and isolated hypha | ||
P9 | 13.4 | unreported | unreported | positive | / | negative | negative | negative | undetected | undetected | Lung tissue culture: Cryptococcus neoformans | / | A ball of fungus + cryptococcus | Pneumoniae cryptococcosis with fungal spherules A ball of fungus + cryptococcus | Pulmonary cryptococcosis complicated with pulmonary aspergillosis A ball of fungus + cryptococcus And PCR confirmed Aspergillus infection | ||
P10 | unreported | unreported | unreported | unreported | / | negative | / | negative | unreported | unreported | negative | / | Two fungal lesions in lung tissue, one was cryptococcal lesion, the other was aspergillus lesion | Undefined | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Two fungal lesions in lung tissue, one was cryptococcal lesion, the other was aspergillus lesion | ||
P11 | unreported | unreported | unreported | 1: 640 | / | negative | / | unreported | unreported | 3.258 | negative | / | / | Pulmonary cryptococcosis Cryptococcal antigen test 1:640 | Pulmonary cryptococcosis complicated with pulmonary aspergillosis Cryptococcal antigen test 1:640 BALF-GM test was 3.258 And Flucytosine + amphotericin B liposomes treat aggravation of symptoms and CT findings | ||
Fig. 2
Histopathological findings and CT results of the patient. A: From P2, found in a single tissue sample with cryptococcus and Aspergillus infection. The lung tissue sent for examination showed foci of coagulative necrosis, in which refractory strong spores were seen, and neutrophilic exudates, abscess formation, in which sharply branched hyphae and spores were also seen, and eosinophils and lymphocyte infiltration in the adjacent lung tissue. The histologic changes were those of pulmonary cryptococcosis combined with Aspergillus infection. B: The patient’s CT results are arranged in chronological order. The patient’s CT results are arranged in chronological order. The sequence is as follows: initial diagnosis of pulmonary cryptococcosis, diagnosis of pulmonary cryptococcosis combined with pulmonary aspergillosis infection, and postcure imaging
×
![]()
CT showed no lesion change in 2 patients after the initial treatment, lesion enlargement in 2 patients after treatment, first reduction and then enlargement in 1 patient, and unchanged lesion in 1 patient after reduction. Five of the 11 patients had multiple nodules or mass shadows, and 1 patient had a mass-like density increase, consistent with typical CT manifestations of pulmonary aspergillosis or pulmonary cryptococcosis. Nine of the 11 patients had radiographic findings that showed cystic lesions, with 2 patients showing thick-walled cavities, one of which had a spike, and 2/11 showed nodular cavity lesions, consistent with the typical CT manifestations of pulmonary aspergillosis. A total of 3/11 lesions were concentrated under the pleura, presenting as infiltrative shadows or nodular cavities. The CT characteristics of 5 patients from our hospital showed that the lesion was initially considered cryptococcus, which was partially absorbed after anti-cryptococcus therapy. After further treatment, the lesion was enlarged and finally diagnosed as complicated with Aspergillus infection (Fig. 2B).
Anzeige
Treatment and outcome of pulmonary cryptococcosis complicated with pulmonary aspergillosis
There were 11 patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis. Among them, five were initially treated with fluconazole, which was partially effective, but then there was either an increase in lesions or no change. One patient underwent a lobectomy after the initial treatment was ineffective, and histopathology confirmed mixed infection of Cryptococcus and Aspergillus. The patient was cured after receiving voriconazole treatment for one year. One patient was initially treated with voriconazole for 5 months without improvement and then switched to fluconazole for 3 months without improvement. After histopathological diagnosis, the patient was treated with voriconazole for one year and was cured. (Patients with liver enzyme CYP2C9 enzyme activity had the high, fast metabolic type. The blood concentrations of previous medication were not monitored, and voriconazole did not reach the therapeutic dose.)Three patients were initially treated with amphotericin B. One patient was treated with amphotericin B alone after a diagnosis of a mixed infection with Cryptococcus and Aspergillus, but the lesions increased. The patient underwent a lobectomy and continued to receive amphotericin B treatment, resulting in improvement. One patient was treated with a combination of flucytosine and amphotericin B. After one month of treatment with fluconazole instead of flucytosine on the basis of no involvement of the central nervous system, antifungal drugs were discontinued. Two weeks later, the patient’s symptoms and imaging worsened, and voriconazole was used instead, resulting in improvement. One patient was directly treated with a combination of amphotericin B and fluconazole after a diagnosis of a mixed infection consisting of Cryptococcus and Aspergillus. One patient underwent a lobectomy after routine anti-infection and anti-tuberculosis treatment was ineffective and was then treated with amphotericin B and fluconazole after surgery, resulting in cure. One patient was directly treated with lobectomy. Four patients had effective treatment with antifungal drugs after excision of the lesion tissue by lobectomy. Voriconazole monotherapy was mostly effective, with a cure/improvement rate of up to 54.5% (6/11) (Table 1).
Discussion
In this study, we included 11 cases of combined pulmonary cryptococcosis and aspergillosis, which are uncommon globally. Reports mainly focus on immunocompromised hosts or patients using immunosuppressive agents. We reviewed 5 cases of pulmonary cryptococcosis combined with aspergillosis in our hospital, reflecting the emerging trend of pulmonary fungal diseases in immunocompetent hosts. These patients were all from the immunocompetent population, with an average age of 42 years, ranging from 32 to 53 years old, and were mainly middle-aged. Three of them were screened for the disease during physical examination and showed no clinical symptoms. All 5 patients were initially diagnosed with pulmonary cryptococcosis. After treatment, which was primarily with fluconazole, the lesions showed varying degrees of improvement but did not disappear completely. In some patients, the lesions even increased in size. Subsequent rebiopsy confirmed the diagnosis of pulmonary cryptococcosis complicated by pulmonary aspergillosis. The patient recovered after treatment with voriconazole. Therefore, the appearance of fixed or unusually enlarged lesions during the treatment of pulmonary cryptococcosis should raise awareness of the possible presence of concomitant pulmonary aspergillosis.
Both cryptococcosis and aspergillosis are common fungal infections in the respiratory system. Compared to cryptococcosis, the disease classification of aspergillosis is more complex [13]. However, the clinical symptoms of both infections are similar and are mainly respiratory symptoms such as cough, sputum production, shortness of breath, and chest pain (Table 1). aspergillosis mostly lack specific clinical manifestations. Typical CT manifestations include cavities, as well as clear crescent or halo signs. However, early presentations are often dominated by small nodules or granulomas [14]. Cryptococcosis infection is often more localized, with cough, sputum production, and chest tightness being the main clinical manifestations. The CT manifestation is mostly single or multiple nodules or consolidation shadows, with visible bronchial meteorology in the consolidation [15]. Single-fungus lung infections are common in both immunocompetent and immunodeficient populations, and appropriate diagnosis and treatment options are available. However, there are very few reports of mixed fungal infections in immunocompetent populations. The diagnosis of mixed infections is also a cumbersome process. All 5 patients in our centre had improved their symptoms after the first treatment of pulmonary cryptococcal disease, but patients’ clinical symptoms did not completely disappear (Table 1). Even in patients without clinical symptoms at the first diagnosis, clinical symptoms such as cough, sputum production, and chest pain appear. There is a correspondence between clinical symptoms and CT findings at this time point. However, the presence of coinfection cannot be determined from this, and a more detailed diagnostic process is required to make this judgement.
The diagnosis of PC and IC can be challenging, and a comprehensive evaluation including laboratory and radiologic tests is necessary for accurate diagnosis and prompt treatment. Unlike previous reports where the pathological conclusion of mixed infection of pulmonary cryptococcosis and aspergillosis was obtained through lung lobectomy or thoracoscopic lung biopsy after initial empirical treatment was ineffective, in this study, 3 out of 5 patients had pulmonary tissue collected at the lesion site through transbronchial lung biopsy (TBLB). The pulmonary tissue was clearly diagnosed as combined pulmonary cryptococcosis and aspergillosis (Table 1; Fig. 2). One patient was diagnosed through percutaneous lung puncture biopsy guided by CT, and only one patient had to undergo lung lobectomy after the initial fluconazole treatment was ineffective due to the lesion being limited to the lower right lung and fungal culture from bronchoalveolar lavage fluid (BALF) revealing the C. neoformans strain. According to research, compared with thoracoscopic lung biopsy techniques, endoscopic operations through bronchoscopy cause less damage to patients, resulting in a lower probability of pathogenic bacterial dissemination and a relatively better differential effect for the three types of diseases: lung cancer, pulmonary tuberculosis, and pulmonary fungal disease [16]. Meanwhile, percutaneous lung puncture guided by CT can compensate for the blind spots of bronchoscopic lung biopsy in detecting the lower branches of the pulmonary bronchi or peripheral areas [17].
Anzeige
Triazole antifungal drugs such as fluconazole and voriconazole and polyene antifungal drugs such as amphotericin B play an important role in the treatment of pulmonary fungal diseases. In this study, patients presented with nodules, cavities, and increased density in the lungs on CT scans, as well as laboratory tests or histological evidence of cryptococcal infection. The majority of patients were initially diagnosed with pulmonary cryptococcosis, and fluconazole was chosen as the first-line treatment for local therapy, while amphotericin B plus flucytosine was selected as the induction therapy. This treatment covers most Candida and Cryptococcus species but lacks coverage for concomitant Aspergillus infection. As the most common pulmonary fungal infection, pulmonary aspergillosis is associated with high in-hospital mortality rates and prolonged hospital stays, with up to a 40% higher risk of readmission and a high mortality rate (30–60%) for invasive infections [18, 19]. After diagnosing concomitant aspergillosis, patients were given the option of using voriconazole, which resulted in improvement or cure. Voriconazole has a broader spectrum of antibacterial activity than fluconazole, covering Cryptococcus, Aspergillus, and Candida species [20]. Although it is not a first-line drug for neonatal cryptococcosis, it is an effective alternative to fluconazole for improving survival in immunosuppressed animal experiments [21]. Voriconazole is also a potential treatment option for induction therapy in cryptococcal central nervous system infections [22]. In patients with refractory pulmonary cryptococcosis, switching from fluconazole to voriconazole can achieve good therapeutic effects [23]. surgery was not necessary, However, among the 11 patients, some underwent surgery followed by a period of antifungal medication.
If early pathological diagnosis confirms a mixed infection of pulmonary cryptococcosis and pulmonary aspergillosis, there is no difficulty in clinical diagnosis. However, in some cases, patients may initially be diagnosed with pulmonary cryptococcosis, and after a period of treatment, they may experience improvement followed by deterioration or no significant improvement at all. In such situations, further differential diagnosis is needed. Delays in the diagnosis of pulmonary cryptococcosis combined with aspergillosis can cause serious adverse consequences. Cryptococcus breaking through the blood‒brain barrier and the invasive infectious nature of pulmonary aspergillosis often lead to poor prognosis [24]. Therefore, a certain diagnostic process needs to be followed to ensure that patients receive a timely diagnosis of pulmonary cryptococcosis combined with aspergillosis. The following are the differential diagnosis directions we need to consider. Is there drug resistance? Is there immune reconstitution inflammatory syndrome, Tumour, or a Mixed infection? When patients undergo CT and other imaging studies and show symptoms such as patchy density increase, nodular shadows, or cavities in the lungs, evidence of cryptococcal infection can be obtained through bronchoscopy biopsy, percutaneous lung puncture, deep sputum culture, or direct microscopic examination. Certainly, considering the complexity of the patients’ conditions, we recommend more proactive diagnostic methods, with invasive examinations being preferred.
Then the recommended treatment plan for pulmonary cryptococcosis can be followed according to the guidelines [12, 25]. For example, a classic regimen such as monotherapy with fluconazole or combination therapy of amphotericin B and flucytosine induction can be used. If the lesion does not change or increases again after initial treatment, it is necessary to pay attention to the possibility of drug resistance. In the past decade of widespread use of antifungal drugs, more than 30% of cryptococcus isolates are no longer sensitive to fluconazole [26]. This situation is particularly common in HIV-positive patients, so it is necessary to reconsider the treatment plan based on culture and drug sensitivity results [27]. In addition, the immune reconstitution inflammatory syndrome (IRIS) of HIV-positive patients should not be ignored. In hospitalized HIV-positive patients, the incidence of pulmonary cryptococcosis is 11%. In HIV-infected patients with concomitant pneumonia, the proportion of serum cryptococcal antigen-positive individuals is as high as 13% [28]. Tumours and mixed infections still need to be considered because the presentation of lung cancer and pulmonary fungal disease is similar, but their treatment methods differ significantly, requiring an accurate diagnosis. The imaging features of lung cancer and pulmonary fungal disease are mainly characterized by pulmonary shadows or masses, and laboratory tests often lack specific indicators. Therefore, if there is an increase in laboratory indicators related to lung cancer or if the patient experiences symptoms such as pleural effusion or lung collapse, a more aggressive examination of the pulmonary lesion needs to be carried out again, such as lung biopsy under thoracoscopy, to further clarify the diagnosis (Fig. 3).
Fig. 3
Diagnostic idea diagram of pulmonary cryptococcal disease after initial treatment is ineffective
×
![]()
Anzeige
In summary, the coexistence of pulmonary cryptococcosis and pulmonary Aspergillus disease is rare but potentially life-threatening in both immunocompetent and immunodeficient patients. Our article also has some shortcomings. The number of patients included in this retrospective study was small, and some clinical data were incomplete. For patients diagnosed first with Cryptococcus and then Aspergillus, it is still unclear whether it is a coinfection or a secondary infection; However, for the first time, this study systematically reviewed the infection characteristics and treatment methods of pulmonary cryptococcosis complicated with concomitant pulmonary aspergillosis at all ages. The aim of this study was to provide a basis for the early diagnosis and accurate treatment of such patients. Further research is needed for optimal management of this rare but important clinical entity.
Acknowledgements
The authors would like to thank Drs. Su Danhong, Gu Yingying, and Zeng Qingsi from the Department of Microbiology Laboratory, the Pathology Laboratory, the Imaging Service of the First Affiliated Hospital of Guangzhou Medical University.
Declarations
Ethical approval
Ethical approval of the study protocol was granted from the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (number 2019-20; Guangzhou, China). Written informed consent was obtained from each participant. Our studies were performed in accordance with relevant guidelines and regulations.
Consent for publication
Written informed consent was obtained from the patients and their families for publication of this case report and any accompanying images.
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.